Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
10.50
+0.22 (2.14%)
Jul 2, 2026, 10:32 AM EDT - Market open
Ginkgo Bioworks Holdings Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 143.86 | 167.2 | 561.57 | 944.07 | 1,316 | 1,550 |
Short-Term Investments | 229.59 | 255.42 | - | - | - | - |
Cash & Short-Term Investments | 373.46 | 422.62 | 561.57 | 944.07 | 1,316 | 1,550 |
Cash Growth | -27.75% | -24.74% | -40.52% | -28.25% | -15.11% | 307.04% |
Accounts Receivable | 20.27 | 24.26 | 22.44 | 17.9 | 82.47 | 136.14 |
Inventory | - | - | - | - | - | 3.36 |
Other Current Assets | 16.23 | 24.96 | 18.73 | 39.78 | 51.82 | 33.54 |
Total Current Assets | 409.96 | 471.84 | 602.74 | 1,002 | 1,450 | 1,723 |
Net Property, Plant & Equipment | 516.82 | 528.29 | 598.16 | 394.99 | 715.54 | 145.77 |
Other Intangible Assets | 48.86 | 53.48 | 72.51 | 82.74 | 111.04 | 21.64 |
Goodwill | - | - | - | 49.24 | 60.21 | 21.31 |
Long-Term Investments | - | - | - | 78.57 | 113.73 | 115.23 |
Other Long-Term Assets | 42.73 | 51.02 | 55.34 | 58.06 | 88.73 | 43.99 |
Total Assets | 1,033 | 1,120 | 1,377 | 1,665 | 2,539 | 2,071 |
Accounts Payable | 16.31 | 10.57 | 14.17 | 9.32 | 10.45 | 8.19 |
Accrued Expenses | 48.38 | 66.46 | 65.39 | 110.05 | 114.69 | 93.33 |
Unearned Revenue | 14.91 | 18.95 | 27.71 | 44.49 | 47.82 | 33.24 |
Total Current Liabilities | 79.6 | 95.97 | 107.27 | 163.86 | 172.96 | 134.76 |
Long-Term Leases | 410.7 | 417.08 | 438.77 | 221.84 | 413.26 | 22.28 |
Other Long-Term Liabilities | 99.63 | 98.06 | 115.36 | 182.5 | 216.83 | 346.57 |
Total Long-Term Liabilities | 510.33 | 515.14 | 554.13 | 404.33 | 630.08 | 368.85 |
Total Liabilities | 589.92 | 611.11 | 661.39 | 568.19 | 803.04 | 503.61 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.19 | 0.16 |
Additional Paid-in Capital | 6,675 | 6,657 | 6,555 | 6,386 | 6,136 | 3,805 |
Accumulated Other Comprehensive Income | 1.19 | 1.85 | -1.81 | 1.48 | -2.63 | -1.72 |
Retained Earnings | -6,233 | -6,150 | -5,838 | -5,291 | -4,398 | -2,298 |
Total Common Shareholders' Equity | 443.15 | 508.59 | 716.06 | 1,097 | 1,736 | 1,505 |
Minority Interest | - | - | - | - | - | 62.01 |
Shareholders' Equity | 443.15 | 508.59 | 716.06 | 1,097 | 1,736 | 1,567 |
Total Liabilities & Equity | 1,033 | 1,120 | 1,377 | 1,665 | 2,539 | 2,071 |
Total Debt | 410.7 | 417.08 | 438.77 | 221.84 | 413.26 | 22.28 |
Net Cash (Debt) | -37.24 | 5.54 | 122.81 | 722.24 | 902.54 | 1,528 |
Net Cash Growth | - | -95.49% | -83.00% | -19.98% | -40.92% | 319.38% |
Net Cash Per Share | -0.66 | 0.10 | 2.37 | 14.86 | 21.49 | 44.92 |
Book Value | 443.15 | 508.59 | 716.06 | 1,097 | 1,736 | 1,505 |
Book Value Per Share | 7.80 | 9.17 | 13.80 | 22.57 | 41.34 | 44.26 |
Tangible Book Value | 394.29 | 455.11 | 643.55 | 965.17 | 1,565 | 1,462 |
Tangible Book Value Per Share | 6.94 | 8.21 | 12.40 | 19.86 | 37.27 | 43.00 |